Stocchi Mauro sold $293K of STVN

Stocchi Mauro (See Remarks) sold 13,649 shares of Stevanato Group S.p.A. (STVN) at $21.50 ($0.29M total) on 2026-09-28.

Original reporting
SEC EDGAR · Stocchi Mauro
Published Sep 30, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STVN
Bearish
medium confidence
Mentioned
$STVN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNBearishLow
01

Why it matters

The disclosed sale is modest in size and may not materially affect the stock price, but it provides a data point for monitoring insider activity.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: after-hours filing on 2026-09-30

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$STVNBearishMedium confidence
Context

Officer Mauro Stocchi sold 13,649 shares of Stevanato Group at $21.50 each, total $293,453.50, reducing his holdings to 400,000 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The transaction size is relatively small for a mid‑cap issuer and represents a reduction in insider ownership, which can be interpreted as a weak signal.

Market effects

Minimal impact on the medical device sector.

Limited to investors tracking Stevanato Group.

None

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Stevanato Group S.p.A.

    Italian medical device manufacturer listed on NYSE under STVN.

  • Mauro Stocchi

    Officer of Stevanato Group who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNHighAI 8/10

Stevanato Group Q3 Earnings Call Highlights

Stevanato Group (STVN) expects 2027 revenue growth to moderate to low-single-digit due to GLP-1-related headwinds, but believes growth will normalize beyond 2027. The company reaffirmed its 2026 guidance, forecasting revenue of €1.26B-€1.28B and adjusted EBITDA of €335M-€345.2M. It is ramping up manufacturing investments and working on over 50 GLP-1-related programs with 30 global customers.

$STVNMed

Stevanato (STVN) Q3 2026 Earnings Call Transcript

Stevanato (STVN) reported Q3 2026 earnings, with non-GLP biologics revenue up 30% offsetting GLP-1 declines. Full-year non-GLP biologics revenue rose 13%. The company expects lower GLP volumes in 2027 but strong demand in non-GLP biologics. They are backfilling revenue and expanding production capacity. Engineering segment results were below expectations, but BDS segment performance will offset this.

$STVNMed

Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8%

Stevanato Group SpA (STVN) reported Q3 2026 revenue growth of 8%, but expects lower GLP-1 volumes in 2027 from a single customer, moderating growth. Engineering segment revenue declined 12%, and gross profit margin decreased to 29.1%. The company backfilled most GLP-1 shortfall but expects validation delays. Non-GLP biologics grew 30% in Q3, driven by broad engagement and capacity investments. Alina pen injector and other delivery devices are in validation stages.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q3 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de

HighAI 8/10

Why is Stevanato stock plunging today?

Stevanato Group's stock fell 25.5% to $14.71 after reporting Q3 2026 revenue of €326.1M, up 8% YoY, beating estimates. However, the outlook for 2027 revenue growth was cut to low single digits due to reduced GLP-1-related volumes from a large customer, alarming investors. The company maintained its full-year 2026 revenue guidance of €1.26B to €1.28B.